FDA Class I Recall: HemosIL AcuStar HIT-IgG(PF-4) IVD Reagent (Recall No. Z-0001-2027)

FDA Class I Recall of HemosIL AcuStar HIT-IgG(PF-4): Up to 47% Negative Bias in Patient Samples

Published on October 12, 2026, 09:36. On October 10, 2026, the U.S. Food and Drug Administration (FDA) updated its medical device recall database to classify a recall by Instrumentation Laboratory (part of the Werfen Group) of the HemosIL AcuStar HIT-IgG(PF-4) in vitro diagnostic reagent as a Class I recall, the most serious category. The recall number is Z-0001-2027, event number 99843; the firm initiated the action on September 3, 2026, and the FDA published it on October 10, 2026.

Product and Affected Lots

The product is HemosIL AcuStar HIT-IgG(PF-4), part number 0009800127, an IVD reagent, UDI-DI 08426951126545. The FDA record lists affected lots B40005 (expiry January 16, 2027) and B38062 (expiry November 1, 2026). The same record states that 434 units entered distribution. The recalling firm is Instrumentation Laboratory, located in Bedford, Massachusetts, United States.

FDA-Stated Recall Reason

The FDA-stated reason is that the affected reagent may have an invalid calibration curve or may show a negative average bias of up to approximately 47% in patient samples. In plain terms, test results may be systematically lowered rather than showing random variation. It should be noted that the cause in the FDA database is currently marked as 'Under Investigation by firm.' According to FDA, the recall cause determination may still be modified before the recall is terminated, so it should not be treated as a final root cause at this stage.

Required Actions for Consignees

The firm's disposition requirements for consignees include several steps: check inventory for remaining affected lots; destroy remaining product according to each institution's standard procedures; record the quantity and date of destruction on the enclosed mandatory response tracking form; forward the notice to all laboratory personnel and relevant hospital departments and sites and retain a copy of the notice for reference; and, whether or not any stock remains, complete and return the tracking form within 10 days of receiving the notice. The firm also advises that, because a supply interruption is expected, consignees should determine an alternative HIT antibody testing method as early as possible and may contact their local Werfen representative for transition support.

Recall Timeline

There is another milestone in the timeline: on September 29, 2026, the firm sent an expanded urgent medical device recall notice to consignees by registered mail or email, informing them of additional affected lots while the other disposition requirements remained unchanged. In other words, the action did not end with a single letter: it was initiated on September 3, expanded in lot scope on September 29, and classified and published by FDA on October 10.

Distribution Scope

This is not a single-market issue. According to the FDA record, the product was distributed within the United States to Arkansas, Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Maryland, New Jersey, New York, Pennsylvania, Rhode Island, Tennessee, Washington, and West Virginia, and exported to Austria, Belgium, Switzerland, Costa Rica, Czech Republic, Germany, Denmark, Spain, Finland, France, the United Kingdom, Greece, India, Italy, Jordan, Japan, Korea, Luxembourg, Latvia, Netherlands, Saudi Arabia, Sweden, and Singapore.

Other Regulatory Notices

Other regulators also have public records. In its Field Safety Notices: 7 September to 11 September 2026 list published on September 14, 2026, the UK MHRA included Instrumentation Laboratory's HemosIL AcuStar HIT-IgG(PF4-H), with a notification date of September 3, 2026 and MHRA reference 40740115. The Saudi Food and Drug Authority (SFDA) also included the product and its authorized representative information in its NCMDR Weekly Update published on September 13, 2026. Both point to the same lot-level field safety notice.

Scope Boundary

It is important to draw a clear boundary: this article discusses the recall of specific reagent lots (B40005 and B38062) and alternative testing arrangements. It should not be used to infer that all HIT antibody testing methods have the same problem, nor to draw conclusions about any laboratory's specific test report. Whether a given report is affected must be checked against the lot number, test date, and the original firm notice.

Sources and Applicability Notes

Sources:

• U.S. Food and Drug Administration (FDA) — Medical Device Recall Database, Class 1 Device Recall HemosIL AcuStar HIT-IgG(PF-4), Recall No. Z-0001-2027, Event No. 99843, published October 10, 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=222721
• U.S. Food and Drug Administration (FDA) — Enforcement Reports. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/enforcement-reports
• Medicines and Healthcare products Regulatory Agency (MHRA) — Field Safety Notices: 7 September to 11 September 2026, published September 14, 2026. https://www.gov.uk/drug-device-alerts/field-safety-notices-7-september-to-11-september-2026
• Saudi Food and Drug Authority (SFDA) — NCMDR Weekly Update, September 13, 2026. https://sfda.gov.sa/sites/default/files/2026-09/%28WU2638%29%20NCMDR%20Weekly%20Update%2013%20September%202026.pdf

Verification scope and access date: This verification accessed the FDA recall database event record page (including lot numbers, distributed quantity, distribution countries, disposition requirements, and timeline), the FDA Enforcement Reports entry page, the MHRA field safety notice list page, and the SFDA NCMDR weekly update PDF; the access date was October 12, 2026 (Beijing time). Verification is based on the text presented on the official pages at that time.

Applicability note: This article is an interpretation of public regulatory information, intended to explain the content and scope of this recall. It does not constitute a conclusion or commitment regarding any specific product, company, laboratory test result, or registration application. Product lot numbers, scope, cause determination, and follow-up actions are subject to the official original text; FDA has noted that the cause determination may change as the investigation and recall progress, and related information may change with subsequent official updates.

AIMEILI Regulatory Interpretation and Business Impact

Regulatory Interpretation

A Class I recall is FDA's most serious recall classification, used when there is a reasonable probability that use of or exposure to the affected product will cause serious adverse health consequences or death. For an IVD reagent such as HemosIL AcuStar HIT-IgG(PF-4), a possible invalid calibration curve or negative bias of up to approximately 47% in patient samples raises concerns about false-negative or falsely low HIT antibody results. In the clinical setting, under-detection of HIT antibodies could delay diagnosis and treatment of heparin-induced thrombocytopenia, a condition associated with thromboembolic risk. Regulators therefore expect rapid consignee notification, effective inventory reconciliation, destruction or return of affected lots, and documented recall effectiveness checks.

The FDA record's 'Under Investigation by firm' status means the root cause is not final. Regulatory affairs teams should monitor FDA updates and align their internal health hazard evaluation, risk assessment, and CAPA with the evolving investigation. The recall also appears in MHRA and SFDA notices, so global regulatory reporting and field safety corrective action coordination are necessary. Manufacturers and authorized representatives should ensure that lot-level traceability, UDI-DI records, distribution lists, and regulatory notifications are consistent across jurisdictions.

Business Impact

For manufacturers and distributors, the immediate business impact includes supply interruption, quarantine and reverse logistics, customer notifications, and possible replacement or alternative product demand. Consignees are required to return tracking forms within 10 days, and failure to do so can affect recall effectiveness checks and regulatory compliance. Distributors should assess inventory exposure by lot, confirm whether affected units remain in stock, and coordinate with local Werfen representatives or the manufacturer for transition support.

For laboratories and CROs, the recall may require implementation of alternative HIT antibody testing methods, verification or validation of replacement assays, revision of standard operating procedures, and review of affected test results. If affected lots were used in clinical trials or research studies, sponsors and CROs should assess protocol deviations, sample re-testing, data integrity, and safety reporting obligations. Clinical laboratories should check lot numbers and test dates against the firm notice before determining whether individual patient results are affected.

For regulatory affairs teams, the key priorities are global recall reporting, coordination with national competent authorities, documentation of field action records, and preparation for audits or inspections. A Class I recall often triggers heightened scrutiny of quality systems, supplier controls, calibration and quality control procedures, complaint handling, and post-market surveillance. Companies should evaluate whether similar risks exist in other lots or related products and should update risk management files and post-market surveillance plans accordingly.

Overall, this event highlights the need for robust IVD lot traceability, rapid field action execution, and cross-border regulatory communication. Companies affected directly or indirectly should maintain a current recall file, monitor official updates from FDA, MHRA, SFDA, and other authorities, and ensure that business continuity plans address alternative testing and customer support during supply interruptions.